Stemline Therapeutics (STML) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. SPY
7. CVS
8. UNH
9. TMUS
10. LMT

Go back to Stemline Therapeutics (STML) Misses Q4 EPS by 1c

Jefferies Cuts Price Target on Stemline Therapeutics (STML) Following 4Q Report

March 16, 2016 9:20 AM EDT

Jefferies maintained a Buy rating on Stemline Therapeutics (NASDAQ: STML), and cut the price target to $23.00 (from $30.00), following the company's 4Q. STML continues to evaluate SL-401. STML reported a 86% ORR in the potentially pivotal BPDCN trial last December at ASH. Management... More

Wedbush Remains Bullish as Stemline Therapeutics (STML) Reports In-Line 4Q - PT to $15

March 15, 2016 7:51 AM EDT

Wedbush maintained an Outperform rating on Stemline Therapeutics (NASDAQ: STML), and cut the price target to $15.00 (from $19.00), following the company's 4Q earnings report. STML reported a net loss of ($0.58) per share, in line with consensus' estimate of ($0.57). Management is expecting multiple clinical updates in 2016.... More